Chemomab Therapeutics (CCMB) Q1 2026 earnings summary

Executive summary

• Presented new clinical and translational data at major medical meetings, confirming nebokitug's disease-modifying potential in PSC and suggesting added benefit for patients with co-existing IBD.

• Advanced multiple partnering discussions for nebokitug, with ongoing strategic evaluations.

Financial highlights

• Cash, cash equivalents, and short-term bank deposits totaled $8.0 million as of March 31, 2026, expected to fund operations through Q1 2027.

• R&D expenses were $0.9 million in Q1 2026, down from $2.5 million in Q1 2025, reflecting the wind-down of the Phase 2 SPRING trial.

• G&A expenses were $0.9 million in Q1 2026, compared to $1.0 million in Q1 2025.

• Net loss for Q1 2026 was $1.8 million, or less than $0.01 per share, compared to $3.3 million in Q1 2025.

• 576,030,200 ordinary shares issued and outstanding as of March 31, 2026.

Outlook and guidance

• Existing liquidity is expected to support operations through the end of Q1 2027.

• Continued focus on advancing nebokitug through strategic partnerships and further clinical development.